



Novaerus Portable Air Disinfection Units

KILL AIRBORNE CORONAVIRUSES AND OTHER PATHOGENS AT THE DNA LEVEL

Closing the Infection Control Loop



PROBLEM:

- SARS-CoV-2 (Covid-19 / Coronavirus) can be transmitted through the AIR: washing hands and cleaning surfaces are not enough
- Patients and staff may be asymptomatic carriers
- Dentists need to return to work while ensuring their safety, as well as the health & safety of their staff and patients

Close the Infection Control Loop



SOLUTION:

Novaerus portable medical-grade air disinfection devices:

- Rapidly neutralize ALL airborne pathogens by attacking them at the molecular level
- Have been proven, via independent laboratory testing, to reduce 99.99% of airborne MS² Bacteriophage (a surrogate for coronavirus)
- Over **48 independent laboratory tests and clinical trials** from around the world have proven that Novaerus devices kill:

Bacteria

such as Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile


Fungi

such as
Aspergillus
niger

Viruses

influenza, **coronaviruses**, norovirus, measles and tuberculosis

Mold



DISINFECT:
HANDS + SURFACES + AIR



Advantages





NOVAERUS DEVICES ARE:

- Portable
- **Easy to install** (simply plug it in) and ready for immediate implementation
- **Safe** around the most vulnerable patients
- Not only kill airborne bacteria, viruses, mold and fungi, but they also eliminate volatile organic compounds (VOCs), leaving your place of work odour-free
- Inexpensive to operate (the two smaller models do not have filters and therefore have no ongoing operating costs)
- Effective independent of the installed HVAC system
- Relatively quiet

Summary: Independent testing results





Novaerus' devices have been proven, in tests around the world, to be **highly effective** against airborne mould, fungi, bacteria and viruses in:


- 22 independent laboratory tests
- 11 clinical trials
- 16 case studies

Proven effective against SARS-CoV-2



- Novaerus Defend 1050 was shown to reduce MS2 bacteriophage (surrogate for SARS-CoV-2) by 99.99% in 15 minutes.
- Link to 2020 independent laboratory test from Aerosol Research and Engineering Laboratories, U.S.:

https://www.novaerus.com/research/1441



Proven effective against coronaviruses



- The NV900 model was tested at an American independent laboratory on its efficacy on neutralizing bioaerosols
- Test results show that the NV900 was extremely effective at reducing viability of bioaerosols in all conducted studies:
 - 99.87% reduction of Staphylococcus epidermidis bacteria
 - 99.99% reduction of MS2 a surrogate for influenza, norovirus and SARS-CoV (coronavirus)
 - 98.85% reduction of Aspergillus niger mold
 - 86.5% reduction of *Bacillus subtilis* bacteria spore
- Link to study: https://www.novaerus.com/research/238

LABORATORY TESTS

Proven efficacy against airborne viruses



INFLUENZA A REDUCTION

Novaerus Defend 1050 was shown to reduce **99.9% of airborne Infuenza A within the first 10-20 minutes** of operation

Link to independent laboratory test from Airmid Health Group Ltd., Ireland:

https://www.novaerus.com/research/241

MEASLES VIRUS REDUCTION

Novaerus Defend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus, by 99.87% after 25 minutes

Link to independent laboratory test from Airmid Health Group Ltd., Ireland: https://www.novaerus.com/research/1

PHI-X REDUCTION

Novaerus Defend 1050 was shown to reduce **Phi X 174 virus by 98.8% in 30 minutes**

Link to independent laboratory test, Korea Testing Laboratory, South Korea:

https://www.novaeru s.com/research/1363

CLINICAL TESTS

Proven efficacy against airborne viruses



LEOPARDSTOWN PARK HOSPITAL, IRELAND

Over a three-year period, this older people's hospital saw **no outbreaks of Influenza**, **Norovirus, MRSA or** *Clostridium difficile* in wards with Novaerus units installed

Continued **decline in staff sickness** (and therefore absenteeism)

Link to results: https://www.novaerus.com/r esearch/310

RIGSHOSPITALET NEPHROLOGY CLINICS, DENMARK

In the control section with no units, the number of overall infections increased by 35% from 2013 to 2014. In the section with Novaerus units, the number of **overall infections fell 23%** during the same time period.

Link to clinical trial: https://www.novaerus.com/res earch/304

MAMOS DELNE, LITHUANIA

After this kindergarten experienced a rotavirus outbreak that infected 70% of children, it acquired Novaerus units. Two months later, a child became infected with rotavirus. This time, only a handful of children experienced symptoms.

After the trial period ended, the Novaerus units were removed and shortly after, Mamos Delne was hit with another outbreak of rotavirus, this time infecting 100% of the children in the facility. Parents demanded the Novaerus units be reinstalled.

Link to results:

https://www.novaerus.com/research/1341

Benefits of ultra-low energy plasma





Plasma coi

- Novaerus uses cutting-edge non-thermal plasma technology
- Several studies have shown this new technology to be a rapid and effective method to inactivate airborne microbial pathogens
- This technology has been found effective at inactivating pathogens on the surface of medical and dental devices
- Study: International Journal of Molecular Sciences: CLICK HERE FOR LINK to Study
- This technology is included "Handbook of COVID-19 Prevention and Treatment,"
 The First Affiliated Hospital, Zhejiang University School of Medicine, document pages 13, 52: CLICK HERE FOR LINK to Study

Novaerus units are the **ONLY medical devices** on the market that use cutting-edge low-energy plasma technology to disinfect the air.



DISINFECTS THE AIR SAFELY 24/7 IN:

- ✓ Dentist offices
- Operating / procedure rooms
- ✓ Intensive Care Units
- Emergency rooms
- ✓ Patient wards
- ✓ Exam rooms
- ✓ Retirement homes
- ✓ Public waiting rooms
- ✓ Staff rooms and common areas
- ✓ Poorly ventilated areas
- ✓ Public bathrooms
- ✓ Reception desk
- ✓ Individual offices
- ✓ Construction zones

A solution when others fail



OTHER SOLUTIONS

HEPA FILTERS

- Due to the size of SARS-CoV-2 viral particles (0.06 μm to 0.14 μm), HEPA filters in HVAC or portable systems do not provide adequate protection as viral particles can flow through the filters
- HEPA filters do not kill the virus, meaning changing filters becomes a danger and potential source of contagion requiring protective gear

IONIZATION

 Ionization techniques electrically charge pathogens but do not kill them causing viral particles to fall on surfaces and contaminate them

NOVAERUS

- Their patented non-thermal, ultra-low energy plasma technology destroys airborne pathogens (viruses, bacteria, mold, fungi) at the DNA level
- Pathogens are therefore killed in the air and are not deposited onto surfaces
- This plasma technology has been proven to be highly effective at disinfecting surfaces as well
- The two smaller models do not have filters
- The filters in the largest model will contain neutralized pathogens, meaning changing filters is a safe process and protective gear is not required

OTHER STERILIZATION METHODS VS.

Novaerus device performance



1 = Not Effective 5 = Very Effective

	NOVAERUS	Photocatalytic Oxidation	UVGI Cleaner	Sanitization Misting	HEPA Filtration	Ozone	Laminar Air Flow	Carbon Filtration
Harmful byproducts	NO	YES ¹	YES ²	YES	NO	YES ³	NO	NO
Prevents filter colonization	5	3	4	0	0	0	0	0
24/7 bacteria load reduction	5	3	3	0	5	0	0	5
24/7 viral load reduction	5	3	4	0	0	0	0	0
24/7 fungal and bacterial spores reduction	5	3	4	0	5	0	0	5
24/7 odour & VOC neutralization ⁴	5	3	0	0	0	0	0	5
Operating costs for maintenance	LOW	HIGH	HIGH	HIGH	MEDIUM	HIGH	LOW	MEDIUM
Removal of ultra/fine particulates ⁴	5	0	1	1	5	0	0	3

PCO can produce formaldehyde.
 At high levels, UV can create noxious gases and is mutagenic.
 High levels of ozone is unsafe to humans.
 Defend 1050 only.

Protection for every space: 3 sizes





NOVAERUS

All units can be **easily positioned** where they are needed most



PROTECT NV200

PROTECT NV900

How Novaerus units work





ALL MODELS:

- A fan draws air, including contaminated air, over the plasma coils
- The ultra-low energy
 plasma field rapidly
 destroys airborne
 pathogens at the DNA level
- Disinfected air is emitted from the device

LARGER MODEL:

 A series of filters for added protection





Solution:

DEFEND 1050

Defend 1050 Features





BEST FOR:

- ✓ Rapid remediation
- ✓ Situations with high risk of infection
- ✓ Large spaces

FEATURES:

- Uses patented ultra-low energy plasma (6 plasma coils)
- Has a triple-stage Camfil[®] filter system
- A complete solution for air disinfection & VOC and particle removal

AREA COVERAGE:

- 18.6 92.9 m² (4 air changes/hour); 200 1 000 ft²
- 37.2 185.8 m² (2 air changes/hour); 400 2 000 ft²

VOLUME TREATMENT:

- 45 226 m³ (4 air changes/hour); 1 590 7 980 ft²
- 90 452 m³ (2 air changes/hour); 3 180 15 960 ft²

Triple-stage Camfil® filter system



PRE-FILTER

Protects the plasma coils and extends the life of the HEPA filter




STAGE 1

30/30 high efficiency pleated panels, water resistant, 3-month life span* 400×400×50mm

HEPA FILTER

Captures fine particles as small as 0.12µm with 99.95% efficiency



STAGE 2

Very high efficiency MGA grade H13 HEPA, individually tested, 12-month life span* 400×400×110mm

CARBON FILTER

Adsorbs VOCs, odours, and gas pollutants



STAGE 3

High efficiency pleated panels, carbon / molecular, moisture resistant, 4-month life span*, 400x400x50mm

Specifications: Defend 1050



CONSTRUCTION + COLOR

 Precision-cut fabricated metal casing in a white anti-bacterial powder coat finish

DIMENSIONS + WEIGHT

- 93.0 cm(h) x 58.0 cm(w) x 48.0 cm(d) /
 36.6" (h) x 22.8" (w) x 18.9"(d)
- 51 kg / 115 lbs

ELECTRICAL

- 120 volts (60Hz)
- 2m power cord with three-pronged plug

NOISE LEVEL

- 47.9 75.1 dBA at unit
- 38.5 62.9 dBA at 1m away (50db at Fan speed 3)

AIR FLOW

Speed 1 - $181 \text{ m}^3/\text{hr} - 6 392 \text{ ft}^3/\text{hr}$

Speed 2 - $317 \text{ m}^3/\text{hr} - 11 195 \text{ ft}^3/\text{hr}$

Speed 3 - $453 \text{ m}^3/\text{hr} - 15 998 \text{ ft}^3/\text{hr}$

Speed 4 - 679 m^3/hr – 23 979 ft^3/hr

Speed 5 - 906 m^3/hr – 31 995 ft^3/hr

FILTERS

Stage 1: Pre-filter (M5)

- Camfil[®] Part No. 715-00-0203
- 400 (h) x 400 (w) x 48 (d) mm / 15.7" (h) x 15.7" (w) x 1.9" (d)

Stage 2: HEPA filter (H13),

- Camfil[®] Part No. 715-00-0163
- 400 (h) x 400 (w) x 110 (d) mm / 15.7" (h) x 15.7" (w) x 4.3" (d)

Stage 3: Carbon filter (G4)

- Camfil[®] Part No. 715-00-0162
- 400 (h) x 400 (w) x 50 (d) mm / 15.7" (h) x 15.7" (w) x 2" (d)





Solution:

Protect NV900

BEST FOR:

- ✓ Small and medium spaces
- ✓ Killing airborne viruses, bacteria, mold, fungi and VOCs
- ✓ Disinfecting the AIR protecting all patients & staff, including the elderly and vulnerable



Specifications: Protect – NV900



CONSTRUCTION + COLOR

- Precision-cut fabricated metal casing in a white anti-bacterial powder coat finish
- Can be wall-mounted or used with a stand attachment

DIMENSIONS and WEIGHT

- 36.5 cm(h) x 36.5 cm(w) x 11.5 cm(d) / 14.4" (h) x 14.4" (w) x 4.5" (d)
- 4.5kg / 10lbs

ELECTRICAL

- 120 volts (60Hz)
- 2m power cord with three-pronged plug

AIR FLOW VOLUME

- Speed I = 220 m 3 /hr 7,700 ft 3 /hr
- Speed II = $260 \text{ m}^3/\text{hr}$ $9,180 \text{ ft}^3/\text{hr}$

NOISE LEVEL

- Speed I = 40 dB
- Speed II = 45 dB







Solution:

Protect NV200



BEST FOR:

- ✓ Small Spaces
- ✓ Personal protection
- ✓ Mobile Use
- ✓ Killing airborne viruses, bacteria, mold, fungi and VOCs
- ✓ Disinfecting the AIR protecting all patients & staff, including the elderly and vulnerable

Specifications: Protect NV200



CONSTRUCTION + COLOR

- Precision-cut fabricated metal casing in a white anti-bacterial powder coat finish
- Wall-mountable, countertop or stand-alone

DIMENSIONS + WEIGHT

- 28.3 (h) x 13.2 (w) x 10.8 (d) cm / 11.2" (h) x 5.2" (w) x 4.3" (d)
- 3.4kg / 7.5lbs

ELECTRICAL

- 120 volts (60Hz)
- 2m power cord with three-pronged plug

FAN AIR FLOW VOLUME

• $85 \text{ m}^3/\text{hr} - 3,000 \text{ ft}^3/\text{hr}$

NOISE LEVEL

• 35 dB



Proven, effective solution to disinfect air



Novaerus' devices have been proven, in tests around the world, to be highly effective against airborne mould, fungi, bacteria and viruses in:

- 22 independent laboratory tests
- 11 clinical trials
- 16 case studies

Test results show that the NV900 was extremely effective at reducing viability of bioaerosols in all conducted studies:

- 99.87% reduction of *Staphylococcus epidermidis* bacteria
- 99.99% reduction of MS2 a surrogate for influenza, norovirus and SARS-CoV (coronavirus)
- 98.85% reduction of Aspergillus niger mold
- 86.5% reduction of *Bacillus subtilis* bacteria spore

Novaerus devices are the **most effective way** on the market to close the infection loop by killing airborne pathogens.

Contact us





www.fertitechcanada.com

514 507-9659

orders@fertitechcanada.com

PATRICK CHEBLI

President 514.575.7961

patrick@fertitechcanada.com

KATE ARCHER

Managing Director 514.979.4992

kate@fertitechcanada.com



APPENDIX A

22 Independent Laboratory Tests



SARS-CoV-2 REDUCTION

- Novaerus Defend 1050 was shown to reduce MS2 bacteriophage (surrogate for SARS-CoV-2) by 99.99% in 15 minutes.
- Link to independent laboratory test from Aerosol Research and Engineering Laboratories, U.S.: https://www.novaerus.com/research/1441

BIOAEROSOLS REDUCTION

- Novaerus Protect 900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger (98.85% reduction), and Bacillus subtilis endospores (86.5% reduction).
- Link to independent laboratory test from Aerosol Research and Engineering Laboratories, U.S.: https://www.novaerus.com/research/238



AIR EXCHANGE

- Novaerus Protect 900 **cleaned 100% of the air** in a room of 22.65 m³ (800 ft³) in 21-24 minutes, dependent on fan speed.
- Link to independent laboratory test from Cork Institute of Technology, Ireland: https://www.novaerus.com/research/835

AIRBORNE ALLERGEN REDUCTION

- Novaerus Protect 900 was shown to **reduce overall allergens by 41.16%,** including house dust mites, feline dander, canine dander, and pollen.
- Link to independent laboratory test from Indoor Biotechnologies Ltd., U.K.: https://www.novaerus.com/research/237

ASPERGILLUS NIGER SPORE REDUCTION

- Novaerus Defend 1050 was shown to reduce 99.99% of aerolized Aspergillus niger spores in 30 minutes.
- Link to independent laboratory test, Aerosol Research and Engineering Laboratories, U.S.: https://www.novaerus.com/research/314



CLOSTRIDIUM DIFFICILE SPORE REDUCTION

- Novaerus Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and > 99.99% after 40 minutes.
- Link to independent laboratory test from Airmid Health Group Ltd., Ireland: https://www.novaerus.com/research/830

ESCHERICHIA COLI (E. COLI) DEACTIVATION

- Novaerus devices caused severe damage to cell structure of aerolized *Escherichia* Coli (E. Coli) & bacterial reculture experiments **confirmed inactivation of airborne** *E. coli* upon treating with Novaerus device.
- NASA Ames Research Center, U.S.: https://www.novaerus.com/research/239

FORMALDEHYDE REDUCTION

- Novaerus Defend 1050 had an average net LOG reduction of 2.52 LOG across four tests and **formaldehyde levels** reached 0.00 ppm in an average of 1.1 minutes.
- Link to independent laboratory test from Aerosol Research and Engineering Laboratories, U.S.: https://www.novaerus.com/research/704



FORMAL DEHYDE REDUCTION

- Novaerus Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment.
- Link to independent laboratory test from Avomeen Analytical Services, U.S.: https://www.novaerus.com/research/240

INFLUENZA A REDUCTION

- Novaerus Defend 1050 was shown to reduce 99.9% of airborne Infuenza A within the first 10-20 minutes of operation
- Link to independent laboratory test from Airmid Health Group Ltd., Ireland: https://www.novaerus.com/research/241

MEASLES VIRUS REDUCTION

- Novaerus Defend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for **Measles virus**, by 99.87% after 25 minutes
- Link to independent laboratory test from Airmid Health Group Ltd., Ireland: https://www.novaerus.com/research/1314



METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) REDUCTION

- The Novaerus Protect 800/900 **reduced 99.99% of Methicillin-resistant** *Staphylococcus Aureus* (MRSA) bacteria over the course of four hours.
- Link to independent laboratory test, Microbac Laboratories, Inc., U.S.: https://www.novaerus.com/research/243

MYCOBACTERIUM TUBERCULOSIS BACTERIA REDUCTION

- Novaerus Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by
 97% after 30 minutes of operation.
- Link to independent laboratory test, Airmid Health Group Ltd., Ireland: https://www.novaerus.com/research/698

MYCOBACTERIUM TUBERCUI OSIS INACTIVATION

- The Novaerus Protect 200 rendered all *Mycobacterium tuberculosis* non-viable.
- Link to independent laboratory test, Qualilife Diagnostics, India: https://www.novaerus.com/research/269



NITROGEN DIOXIDE REDUCTION

- The Novaerus Defend 1050 reduced the chamber concentration of Nitrogen Dioxide (NO₂) to **0.0 ppm in 7.5 minutes** in all three trials.
- Link to independent laboratory test from Aerosol Research and Engineering Laboratories, U.S.: https://www.novaerus.com/research/696

PARTICLE REDUCTION

- Novaerus Defend 1050 removed 99% of PM_{2.5} within 6.26 minutes and 99% of PM_{1.0} within 6.33 minutes
- Link to independent laboratory test, Camfil Laboratories Tech Center, Sweden: https://www.novaerus.com/research/315

PHI-X VIRUS REDUCTION

- Novaerus Defend 1050 was shown to reduce Phi X 174 virus by 98.8% in 30 minutes
- Link to independent laboratory test, Korea Testing Laboratory, South Korea: https://www.novaerus.com/research/1363



STAPHYLOCOCCUS EPIDERMIDIS BACTERIA REDUCTION

- The Novaerus Defend 1050 was shown to reduce *Staphylococcus epidermidis* bacteria by **99.9% in 60 minutes**.
- Link to independent laboratory test from Korea Testing Laboratory, South Korea: https://www.novaerus.com/research/1364

STAPHYLOCOCCUS EPIDERMIDIS BACTERIA REDUCTION

- Novaerus Defend 1050 achieved a microbial cell **reduction of 99.94% of** *Staphylococcus epidermidis* within 15 minutes of operation.
- Link to laboratory test, Novaerus Research and Development Labs, Ireland: https://www.novaerus.com/research/695

STAPHYLOCOCCUS EPIDERMIDIS AND ASPERGILLUS NIGER REDUCTION

- Novaerus caused **severe size and shape change to cell structure** of aerosolized *Staphylococcus epidermidis and Aspergillus* niger, possibly resulting in destruction of cellular components and eventually to cell death. A similar effect was found on the fungal spores.
- Link to independent laboratory test, NASA Ames Research Center, U.S.: https://www.novaerus.com/research/268

Laboratory tests prove efficacy against airborne pathogens 8



STAPHYLOCOCCUS EPIDERMIDIS BACTERIA REDUCTION

- Novaerus units were shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes.
- Link to independent laboratory test, University of Huddersfield, U.K.: https://www.novaerus.com/research/267

VOC REDUCTION

- Novaerus Defend 1050 achieved 90% VOC reduction after 6 16 minutes, dependent on fan speed.
- Link to laboratory test, Camfil Laboratories Tech Center, Sweden: https://www.novaerus.com/research/834



APPENDIX B

11 Clinical Trials



EVALUATION OF THE NOVAERUS TECHNOLOGY IN A DIALYSIS CENTRE, PORTUGAL

- Novaerus devices reduce VOCs by 93%, airborne bacteria by 87% and moulds by 67%.
- Link to results: https://www.novaerus.com/research/311

EVALUATION OF THE NOVAERUS TECHNOLOGY IN AN EMERGENCY HOSPITAL, ROMANIA

- Novaerus unites were shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87%.
- Link to clinical trial: https://www.novaerus.com/research/312

LEOPARDSTOWN PARK HOSPITAL, IRELAND

- Over a three-year period, this older people's hospital saw no outbreaks of Influenza, Norovirus, MRSA or Clostridium
 difficile in wards with Novaerus units installed
- Continued decline in staff sickness (and therefore absenteeism)
- Link to results: https://www.novaerus.com/research/310



EVALUATION OF THE NOVAERUS TECHNOLOGY IN A HOSPITAL, ENGLAND

- Novaerus Protect 800/900 devices **reduce environmental surface MRSA by 97%** and reduces environmental surface TVC and **environmental air** MRSA.
- Link to results: https://www.novaerus.com/research/303

EVALUATION OF THE NOVAERUS TECHNOLOGY IN AN INFECTIOUS DISEASE HOSPITAL, ROMANIA

- Novaerus devices were shown to reduce airborne bacteria and fungi by 96%.
- Link to clinical trial: https://www.novaerus.com/research/308

EVALUATION OF THE NOVAERUS TECHNOLOGY IN INTENSIVE CARE, POLAND

- Novaerus' ultra-low energy plasma technology was shown to significantly reduce the number of microorganisms.
- Link to clinical trial: https://www.novaerus.com/research/305



RIGSHOSPITALET NEPHROLOGY CLINICS, DENMARK

- In the control section with no units, the number of overall infections increased by 35% from 2013 to 2014. In the section with Novaerus units, the number of **overall infections fell 23%** during the same time period
- Link to clinical trial: https://www.novaerus.com/research/304

EVALUATION OF THE NOVAERUS TECHNOLOGY IN AN OPHTHALMOLOGY OPERATING ROOM, EGYPT

- Novaerus devices reduced bacterial colony count in both the rooms that were being used and those that were empty.
- Link to results: https://www.novaerus.com/research/1189

EVALUATION OF THE NOVAERUS TECHNOLOGY IN A PAEDIATRIC DEPARTMENT, POLAND

- Novaerus devices effectively **reduced the number of airborne pathogens by 61%** in the admission room of the Paediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases.
- Link to results: https://www.novaerus.com/research/306



EVALUATION OF THE NOVAERUS TECHNOLOGY IN A PULMONOLOGY DEPARTMENT, HUNGARY

- Novaerus devices reduced CFU rates by 82% and fungi count by 93% after two months of operation.
- Link to results: https://www.novaerus.com/research/309

EVALUATION OF THE NOVAERUS TECHNOLOGY IN A SPECIALISED HOSPITAL, POLAND

- Novaerus devices significantly reduces the number of microorganisms as well as eliminated unwanted odours.
- Link to results: https://www.novaerus.com/research/307



APPENDIX A

16 Case Studies



BROWARD CHILDREN'S CASE STUDY, UNITED STATES

- This 20-month study showed after implementating Protect 900 units in selected rooms and areas, the total number of nosocomial respiratory infections decreased by 51.72%.
- Link to results: https://www.novaerus.com/research/220

CANTERBURY TOWER CASE STUDY, UNITED STATES

- In the 7-month period after installation individual NV200 units in targeted patient rooms, **nosocomial respiratory** infections decreased by 93.33%.
- Link to results: https://www.novaerus.com/research/219

EDGEHILL NURSING AND REHABILITATION CENTER STUDY, UNITED STATES

- This 24-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology.
- Link to results: https://www.novaerus.com/research/221



HAUS AN DER TRAISEN NURSING HOME STUDY, AUSTRIA

- Since 2014, the Haus an der Traisen nursing home has supplemented its existing hygiene protocols with Novaerus air purification units to **help control infection and reduce odour**.
- Link to results: https://www.novaerus.com/research/235

HIALEAH NURSING AND REHAB CENTER, UNITED STATES

- This 24-month study after installation of NV200, NV400 and NV900 units in selected areas, the total number of repeat infections decreased by 37.50%, whereas *C. difficile* infections decreased by 100%.
- Link to results: https://www.novaerus.com/research/222

LINDE HEALTHCARE CASE STUDY, AUSTRIA

- Following a five-month trial with Novaerus devices in a 16-person open office plan, **employee sick time was reduced by 40%**, employees noticed the office was fresh and lacked its previous winter season staleness.
- Link to results: https://www.novaerus.com/research/233



MAMOS DELNE KINDERGARTEN, LITHUANIA

- After this kindergarten experienced a rotavirus outbreak that infected 70% of children, it acquired Novaerus units. Two months later, a child became infected with rotavirus. This time, only a handful of children experienced symptoms
- After the trial period ended, the Novaerus units were removed and shortly after, Mamos Delne was hit with another outbreak of rotavirus, this time infecting 100% of the children in the facility. Parents demanded the Novaerus units be reinstalled
- Link to results: https://www.novaerus.com/research/1341

MANCHESTER MANOR HEALTH CARE CENTER, UNITED STATES

- A 24-month study comparing areas without Novaerus devices and those with Protect 200 and 900 units installed showed that the **total number of nosocomial respiratory infections decreased by 42.86%** with the Novaerus units and the total number of nosocomial *C. difficile* infections decreased by 50% with the units.
- Link to results: https://www.novaerus.com/research/223



MEADOW VIEW NURSING CENTER, UNITED STATES

- This 24-month study showed that after implementing the NV200 and NV900 units in selected areas, the facility's total number of **nosocomial respiratory infections decreased by 77.42%** and nosocomial respiratory infections **decreased 95.65% on the third floor.**
- Link to results: https://www.novaerus.com/research/224

NAAMAN'S CREEK COUNTRY MANOR, UNITED STATES

- This 28-month study showed that after implementation of the NV200, NV400, and NV900 units in selected areas, the total number of **nosocomial respiratory infections decreased 53.01%**, while *C. difficile* infections were reduced by 85.71%.
- Link to results: https://www.novaerus.com/research/225

PAGE REHABILITATION AND HEALTHCARE CENTER, UNITED STATES

- This 29-month study revealed that Novaerus devices NV200 and NV400 in selected areas, reduced the average monthly rate of nosocomial respiratory infections by 75.31%.
- Link to results: https://www.novaerus.com/research/226



SANTE INTERNATIONAL CASE STUDY, ROMANIA

- This case study was performed at the Bucharest Emergency Hospital
- After three months and 336 air samples, locations in the hospital with Novaerus units saw an **89% reduction in airborne** bacteria, 87% reduction in airborne fungi and nearly 100% reduction in airborne *Staphylococcus*.
- Link to results: https://www.novaerus.com/research/234

UNIVERSITY OF SZEGED, FACULTY OF MEDICINE – INTERNAL MEDICINE, HUNGARY

- Novaerus units were placed in four locations in the University of Szeged's Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1. Air samples taken before the trial revealed background pollution levels as high as 2610 cfu/m³ and MRSA levels at 40 cfu/m³, despite the clinic practicing standard hygiene protocol.
- Three days after installing the Novaerus units, background **pollution was reduced by an average of 67% and MRSA** colonies were eliminated completely.
- Link to results: https://www.novaerus.com/research/236



VERNON MANOR HEALTH CARE CENTER, UNITED STATES

- This 24-month study showed the use of NV900 units in main hallways and NV200 units in select patient rooms, reduced the total number of nosocomial respiratory infections by 59.32%.
- Link to results: https://www.novaerus.com/research/227

VILLAGE AT MANOR PARK CASE STUDY, UNITED STATES

- This 23-month study revealed that after implementating the NV900 units in patient rooms, hallways, and dining rooms on the first floor, the facility's total number of **nosocomial respiratory infections decreased by 79.41%.**
- Link to results: https://www.novaerus.com/research/228

WASSAN DENTAL SPECIALITY CENTRE CASE STUDY, OMAN

- Like most dental clinics, Wassan Dental was concerned about high levels of VOCs, particulate, and pathogens in the indoor air as a consequence of routine dental procedures and materials.
- Two weeks after installing Protect 800/900 units in key locations around the practice, staff observed a noticeable reduction in odour and patients noted a fresh quality to the air inside the clinic.
- Link to results: https://www.novaerus.com/research/1190